Fracture Clinical Trial
Official title:
Mean Effective Dose of Rapidly Administered Ketamine for Brief Pediatric Procedural Sedation
The purpose of the study is to find the dose of rapidly administered ketamine in 3 different
pediatric age groups (2-5, 6-11 and 12-17) for abscess drainage and fracture reduction.
Ketamine is the most common drug administered to children to facilitate painful procedures in
the emergency setting because it achieves potent sedation, pain relief and amnesia with
minimal adverse cardiopulmonary effects.(1-5) However, the 1-2 hour recovery period (1,6)
associated with standard ketamine administration guidelines(7) strains work flow because it
requires bedside one-on-one nurse monitoring in a treatment room, tying up these limited and
valuable resources. Consequently, a combination of two other drugs, propofol + fentanyl
(P/F), with recovery of 20-30 minutes, is rapidly gaining popularity for procedural sedation
despite more frequent respiratory depression, apnea and hypotension caused by this
technique.(2,4,8,9)
The investigators believe recovery associated with our novel method for administering
ketamine is significantly shorter than with the standard larger dose more slowly administered
ketamine technique(7). Through the investigators clinical experience, the investigators have
found rapid infusion of smaller than standard doses of ketamine safely achieves the drug's
sedative effect, with the benefit of more rapid recovery due to the use of a smaller dose.
However, this novel technique challenges published beliefs that time of recovery from
ketamine sedation does not differ significantly with the dose administered, within the usual
dose ranges, and that rapid infusion may cause respiratory depression, similar to that seen
with other classes of sedative-analgesic drugs.(7,10) the investigators believe the slow
infusion recommended by standard guidelines(7) requires a larger ketamine dose necessary to
achieve effective sedation, and, consequently, prolongs recovery. It is the prolonged
recovery that has prompted increased use of other less safe but briefer sedatives, such as
propofol/fentanyl. By demonstrating patients recover rapidly with new ketamine technique,
without increased adverse cardiopulmonary effects, the investigators will provide clinicians
with an important new method for ketamine procedural sedation. The investigators believe
clinicians will prefer more rapid recovery ketamine technique because it is safer and reduces
pain and distress better than the propofol/fentanyl combination for sedation.
The investigators complete proposal requires two steps. In Step One, this proposal, the
investigators will determine the minimum effective dose of rapidly infused ketamine that
achieves deep sedation for at least 5 minutes in 95% of children (ED95). Two groups of
patients will be studied: one group is patients undergoing abscess incision and drainage and
the other group is patients undergoing fracture reduction in our Emergency Department. The
investigators believe that the ED95 is different for both the groups as the severity of pain
is different. The investigators will compare the safety and recovery times to published
standard ketamine techniques. In the following study, Step Two, the investigators will
compare this novel technique, in a blinded randomized trial using the ED95 ketamine dose
determined in Step One to the standard ketamine technique to determine if the novel technique
results in significantly shorter recovery without an increase in the frequency of adverse
effects. The study the investigators are proposing in this submission is Step One only.
During fracture reduction in children, the investigators found less distress using
ketamine+midazolam (K/M) sedation (P<0.0001) and less hypoxia (5% vs. 25%) compared to
sedation with fentanyl+midazolam (F/M)(1). Others also found less hypoxia with K/M (4%)
compared to propofol+fentanyl (P/F) (18-31%)(2,4). Because of the greater safety and efficacy
determined in these and similar studies, ketamine is now the most common drug administered
for procedural sedation of children undergoing painful procedures in the ED.(7) For the past
15 years, the investigators have sedated about 2,500 children each year with ketamine in the
St. Louis Children's Emergency Department for setting broken bones, debriding burns, draining
abscesses, and other very painful procedures. Midazolam was co-administered with ketamine in
early studies to reduce dysphoria during recovery, but this practice has since been shown not
to be beneficial. For the past 5-10 years the investigators have used ketamine without
midazolam and have seen no change in how children wake up from ketamine sedation.(6,11)
Ketamine administration in the investigators previous studies (1,3) was similar to recent
recommendations (1.5-2 mg/kg I.V. infused over 30-60 sec)(7). Problematically, while most of
these ED procedures such as fracture reduction, burn debridement, or abscess incision and
drainage, require only 5-10 minutes of deep sedation, this standard ketamine technique
results in recovery periods of 60-120 minutes(1,3,6). During recovery, patients remain in
treatment rooms to be monitored one-on-one by nurses for respiratory depression, airway
obstruction, vomiting and other potentially life-threatening adverse events, thus tying up
these limited resources(10). This long recovery has led to increased use of propofol based
techniques which have more rapid recovery (20-30 minutes) but cause increased respiratory
depression and hypotension and less effective sedation(2-6,9). Because of ketamine's greater
safety and efficacy profile, the investigators have been interested in developing alternative
ketamine administration regimens that result in more rapid recovery, similar to propofol. If
successful in hastening recovery, the investigators believe that the relative lack of
respiratory depression and greater analgesia with ketamine will improve patient safety by
encouraging continued use of ketamine as the preferred technique for procedural sedation in
children undergoing painful procedures in the ED.
To explore new techniques for hastening recovery from sedation, the investigators took
advantage of the uniqueness of ketamine. Rapid administration of opioid and gabaergic drugs
such as fentanyl and propofol significantly augments the drugs' beneficial effects, but it
also markedly increases respiratory depression, apnea and hypotension.(13) Cautions that
rapid infusion of ketamine may cause brief respiratory depression stem from early anesthesia
trials using doses larger than those typically used for sedation.(7) Although not formally
studied, for the past 5 years the investigators have observed no adverse effects with rapid
administration of 0.5-1.5 mg/kg ketamine doses for brief painful procedures like fracture
reduction and abscess incision & drainage in children in the Emergency Unit of St. Louis
Children's Hospital.
Lipophilic drugs used for procedural sedation-analgesia, such as ketamine, fentanyl, and
propofol rapidly diffuse from the bloodstream into the brain. A disproportionately high
percentage of the cardiac output goes to the brain, thus a large portion of a drug injected
intravenously initially goes into the brain's circulation on first pass through the heart and
exerts clinical effects within a single circulation time, usually < 60 seconds. The drug
remaining in the bloodstream circulates throughout the body and diffuses into muscle, bone
and fat, causing the blood concentration to fall. The blood-brain concentration gradient then
favors drug diffusion out of the brain and the patient awakens.
Rapid infusion of sedative drugs increases central nervous system clinical effects by
directing a larger portion of the drug into the brain. A rapidly injected dose of drug
travels as a more concentrated bolus into the brain circulation than a slowly injected dose
that is diluted by the passing blood. With rapid injection, therefore, the initial
blood-brain concentration gradient is greater and a larger portion of the dose initially
enters the brain, causing deeper sedation. Smaller doses, rapidly injected, therefore can be
used to achieve deep sedation similar to that of larger doses injected more slowly. With the
smaller dose, the blood-brain concentration gradient subsequently reverses more rapidly and
"wake up time" is shorter. Because rapid increases in brain concentration of ketamine does
not cause respiratory depression, unlike that seen with fentanyl or propofol, this rapid
infusion technique can be used with ketamine.
The purpose of this research project is to determine formally the minimum dose of ketamine
that, when rapidly infused, achieves 5 minutes of deep sedation in 95% of patients (ED95).
The investigators will use the up and down method (15) which is a standard method in
anesthesiology to find the mean effective dose. Five minutes is typically enough time to
perform these brief painful procedures. The investigators anticipate the ED95 will be smaller
than the standard recommended ketamine dose and thus patients will wake up faster.
Of special note, determination of the "standard dose and rate of administration of
ketamine"(7) has been based upon our and others' studies in which the dose and rate of
infusion of ketamine were not carefully controlled and, in fact, varied widely(1,3,4,7).
Thus, the "standard recommendation for administration of ketamine" is somewhat anecdotal and
has not been precisely determined. Our proposed study will be the first to precisely
determine a minimum effective ketamine dose.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT04470895 -
Impact of Drugs on the Risk of Falls in the Fracture Department of the Paris Saint-Joseph Hospital Group
|
||
Recruiting |
NCT02635022 -
Fragility Fracture Liaison Service and Anti-osteoporosis Medication Monitoring Service Study
|
||
Unknown status |
NCT02013986 -
Effects of Etomidate on Postoperative Circadian Rhythm Changes of Salivary Cortisol in Children
|
Phase 4 | |
Terminated |
NCT01248182 -
Bone to Skin Thickness Study: Obese Versus Normal Population
|
N/A | |
Recruiting |
NCT00969839 -
NovaLign Intramedullary Fixation System (IFS) for the Treatment of Humeral Fractures
|
Phase 4 | |
Completed |
NCT00115180 -
Racial and Ethnic Disparities in Acute Pain Control
|
N/A | |
Completed |
NCT00520442 -
Acute Pediatric Fracture Analgesia Study
|
N/A | |
Not yet recruiting |
NCT06402292 -
Surgical Treatment of Osteoarticular Infections Using Bioactive Bone Substitute
|
N/A | |
Recruiting |
NCT04947722 -
The PREVENT Trial: a Pragmatic Cluster Randomized Controlled Trial of a Multifaceted Fracture Prevention Model for Long-term Care
|
N/A | |
Recruiting |
NCT06107699 -
The CHARM Study-Coordinating Transitions From Hospital for Older Adults With Fractures
|
N/A | |
Completed |
NCT04532580 -
Clinical Validation of Boneview for FDA Submission
|
||
Completed |
NCT04237454 -
Thermal Imaging Compared to Skeletal Survey in Children Below 2 Years
|
N/A | |
Recruiting |
NCT05002335 -
Clinical and Radiological Outcomes of Medacta Shoulder System (BE)
|
||
Completed |
NCT02591043 -
Surgical Treatment of Low Energy Pelvic Fractures in the Elderly
|
N/A | |
Completed |
NCT02933359 -
Osteogenic Profiling of Normal Calvarial Bone
|
||
Completed |
NCT01049191 -
Bone Microarchitecture in Women With and Without Fracture
|
N/A | |
Completed |
NCT03431857 -
Multi Centre Study on TESS V2 Shoulder System
|
||
Recruiting |
NCT04133103 -
Early Mobilisation in the Surgical Robot Assisted Spinal Surgery
|
N/A | |
Completed |
NCT03993691 -
Wrist Fracture Evaluation With a Desktop Orthopedic Tomosynthesis System
|
N/A | |
Active, not recruiting |
NCT01719887 -
Effectiveness and Cost-effectiveness of Surgical Treatment of Humeral Shaft Fractures. Randomized Controlled Trial
|
N/A |